Press Releases

Information on the Annual Financial Statements Biophytis announces that, due to exceptional circumstances related to technical complications in the audit process, the publication of its 2024 annual financial statements has been postponed. The Company requires additional time to complete the audit and certification of its accounts. As a result, Biophytis will publish its 2024 annual financial statements by the end of June 2025. Accordingly, Biophytis has also decided to postpone the date of its Ordinary General Meeting of shareholders. The convening of this meeting will be carried out in accordance with applicable legal procedures. Biophytis has initiated the necessary steps

Postponement of the publication of the annual financial statements Biophytis announces the postponement of the publication of its annual financial statements for the year ended December 31, 2024. Due to the €2.6 million refinancing operation (announced in the press release dated March 26, 2025), the Company had to focus its efforts on the related discussions and negotiations. As a result, the Company is not able to meet the legal deadline for the publication of its 2024 annual financial statements, set for April 30, 2025. Biophytis is making every effort to finalize and publish its financial statements by the end of

Biophytis Confirms the Launch of the Phase 2 OBA Clinical Trial in Obesity Biophytis confirms the launch of the Phase 2 OBA clinical study in obesity, expected to begin as early as possible in 2025. Following the recent €2.6 million capital increase announced on March 26, 2025, and promising preclinical results presented at the 15th International Conference on Frailty and Sarcopenia in Toulouse, Biophytis will continue the clinical development of BIO101 in obesity. The goal is to evaluate the efficacy and safety of BIO101 in reducing muscle strength loss caused by GLP-1 agonists in patients with obesity. As a reminder,

Biophytis announces the settlement and delivery of its €2.6 million private placement NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA, JAPAN AND SOUTH AFRICA Biophytis announces today the settlement and delivery of its private placement in the amount of €2,599,979.72 (including the issuance premium), carried out through the issuance, without preferential subscription rights, of (i) 4,307,614 new ordinary shares of the Company (the “New Shares”), each accompanied by a share subscription warrant (a “Warrant”) (together with the New Share, the “ABSA”), and (ii) 5,692,308 prepaid subscription warrants (the “Prepaid Warrants”), each also accompanied by

Biophytis announces the successful completion of a €2,6 million private placement Capital increase of a total amount of approximately €2,6 million in gross proceeds by issuing 4,307,614 new shares, each with one share warrant attached, at €0,26 per unit, and 5,692,308 pre-funded warrants, each with one share warrant attached, at €0,25 per pre-funded unit; Gross proceeds include €2 million from Armistice, and approximately €0,6 million from a limited number of other qualified investors. Settlement-delivery of the new shares and share warrants expected on March 28, 2025. NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA,